Imaging Center COE

Performance of 68Ga PSMA PET CT to Detect Prostate Cancer and Comparison with 18F Choline PET CT - Manuela Hoffmann

Details
Radiolabeled prostate-specific membrane antigen (PSMA) has proven as a highly accurate method to detect recurrences and metastases of prostate cancer, but there are only sparse data about its diagnostic performance in primary prostate cancer. Manuela Hoffman presents a retrospective study of the diagnostic performance of 68Ga-PSMA PET/CT to detect significant prostate cancer in comparison with 18F...

Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman

Details
Michael Hofman discusses with Alicia Morgans both the diagnostic and therapeutic aspect of prostate specific membrane antigen (PSMA) in prostate cancer. The sensitivity and specificity of the PSMA PET may offer relevant clinical advantages in the diagnosis of prostate cancer while the physical properties of Lutetium 177 may provide advantages therapeutically. Biographies: Michael Hofman, MBBS (Hon...

A Review of Imaging Modalities in Prostate Cancer - Peter Pinto

Details
(Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...

Assessment of Simplified Methods for Quantification of 18F FDHT Uptake Scans in Patients with Metastasized Castrate-Resistant Prostate Cancer - Gem Kramer

Details
(Length of Presentation: 8 min) This presentation represents a study performed to assess if [18F]FDHT PET/CT could be a valuable imaging biomarker in patients with prostate cancer. Biographies: Gem Kramer, Radiology and Nuclear Medicine VU University Medical Center Amsterdam the Netherlands Read the Full Video Transcript {article title="assessment-of-simplified-methods-for-quantification-of-18f-fd...

PSMA-Ligand Uptake in Cervical, Coeliac and Sacral Ganglia as a Pitfall for Lymph Node Metastases in Prostate Cancer Imaging - Christoph Rischpler

Details
( Length of Presentation 7 minutes) Christoph Rischpler presents a study aimed at investigating the PSMA-ligand uptake in PET in cervical, coeliac and sacral ganglia as a pitfall for lymph node metastases in prostate cancer imaging. This patient population consisted of 308 randomly selected patients who underwent Gallium 68 PSMA-PET between October 2012 and March 2014. For image analysis, they det...

PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell

Details
(Length of presentation: 30 min) In an interview with Phil Koo, Robert Flavell describes diagnostic and therapeutic applications of new agents in the management of patients with prostate cancer with initial high-risk diagnosis and biochemical recurrence. Biographies: Robert R. Flavell, MD, Ph.D., Assistant Professor in Residence Department of Radiology, Section of Nuclear Medicine, University of C...

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

Details
(Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

Details
(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...

The Incredible Shrinking nmCRPC - Phillip Koo

Details
(Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...

The Utility of PSMA PET In Prostate Cancer Management- Stefano Fanti

Details
(Length of Discussion: 12 min) Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key poi...